Cutaneous T-cell Lymphoma.
Weiner DM, Rook AH.
Hematol Oncol Clin North Am. 2024 Oct;38(5):1087-1110. doi: 10.1016/j.hoc.2024.05.012. Epub 2024 Jul 29.
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.
J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049.
Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates.
Saleh JS, Subtil A, Hristov AC.
Hum Pathol. 2023 Oct;140:75-100. doi: 10.1016/j.humpath.2023.09.009. Epub 2023 Oct 4.
Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates.
Saleh JS, Subtil A, Hristov AC.
Hum Pathol. 2023 Aug;138:76-102. doi: 10.1016/j.humpath.2023.06.001. Epub 2023 Jun 10.
Cutaneous T-cell Lymphoma.
Pulitzer M.
Clin Lab Med. 2017 Sep;37(3):527-546. doi: 10.1016/j.cll.2017.06.006.
Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma.
Rindler K, Jonak C, Alkon N, Thaler FM, Kurz H, Shaw LE, Stingl G, Weninger W, Halbritter F, Bauer WM, Farlik M, Brunner PM.
Mol Cancer. 2021 Sep 28;20(1):124. doi: 10.1186/s12943-021-01419-2.
Primary Cutaneous Acral CD8(+) T-Cell Lymphoma.
Hathuc VM, Hristov AC, Smith LB.
Arch Pathol Lab Med. 2017 Nov;141(11):1469-1475. doi: 10.5858/arpa.2017-0230-RA.
Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges.
Hague C, Farquharson N, Menasce L, Parry E, Cowan R.
Br J Hosp Med (Lond). 2022 Apr 2;83(4):1-7. doi: 10.12968/hmed.2021.0149. Epub 2022 Apr 14.
Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphoma.
Oymanns M, Elsayad K, Wilms L, Dimmers F, Daum-Marzian M, Abu-Dawud R, Motiei M, Assaf C.
Immunotherapy. 2025 Jun;17(8):551-559. doi: 10.1080/1750743X.2025.2520153. Epub 2025 Jun 24.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group.
Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7.
